Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine-bupivacaine versus nalbuphine-bupivacaine deep serratus anterior plane block after modified radical mastectomy
PACTR202408744793714Phase 2Completed
- Sponsor
- Mansoura University Faculty of Medicine
- Start
- Dec 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dexmedetomidine, nalbuphine and bupivacaine in breast cancer, sponsored by Mansoura University Faculty of Medicine. Primary endpoint: Quality of recovery. Started Dec 2023; status: completed.
02
Drugs
dexmedetomidinenalbuphinebupivacaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202408744793714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408744793714.